BPC-157 vs TB-500
Side-by-side comparison of BPC-157, TB-500 — mechanism, dosing, half-life, side effects, and research status.
| Attribute | BPC-157 Body Protection Compound-157 Recovery | TB-500 Thymosin Beta-4 Synthetic Analogue Recovery |
|---|---|---|
| Basics | ||
| Molecular type | Gastric Pentadecapeptide | Thymic Peptide Analogue |
| Amino acids | 15 | 43 |
| Molecular weight | 1,419.5 Da | 4,921 Da |
| Half-life | ~4 hrs (SC) | Long-acting (days) |
| Route(s) | Subcutaneous, Intramuscular, Oral (research only) | Subcutaneous, Intramuscular |
| Mechanism & Research | ||
| Primary mechanism | BPC-157 exerts its primary effects through upregulation of the nitric oxide (NO) signalling pathway. By promoting NO synthase activity, it drives vasodilation and angiogenesis at injury sites, accelerating the delivery o… | TB-500's primary mechanism involves binding to G-actin (monomeric actin) through its conserved LKKTETQ sequence. By sequestering actin, it regulates cytoskeletal dynamics in ways that promote cell migration — a critical … |
| Research status | Research Compound | Research Compound |
| Evidence summary | The majority of BPC-157 research is preclinical (animal and in vitro). No large-scale randomised controlled trials in humans have been published as of 2026. The FDA's 2024 assessment noted insufficient human safety and e… | TB-500 research spans cardiac regeneration, wound healing, hair follicle regeneration, and musculoskeletal repair. Most data is preclinical. Phase 1/2 trials with native Thymosin Beta-4 for cardiac indications have been … |
| Protocol & Dosing | ||
| Typical dose | 200–500 mcg per injection | 5–10 mg per injection |
| Frequency | Once or twice daily | 2x per week (loading), then weekly |
| Duration | 4–12 weeks | 4–8 weeks |
| Timing | Near injury site when possible | No specific timing requirement |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Prohibited (WADA S0) | Prohibited (WADA S2) |
| Deeper reading | ||
| Related peptides | TB-500, GHK-Cu, KPV, Pentadeca Arginate | BPC-157, GHK-Cu, Thymosin Alpha-1 |
| Full profile | Read full BPC-157 profile → | Read full TB-500 profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.